INKT MINK THERAPEUTICS INC

MiNK Therapeutics to Participate at Upcoming Investor Conferences

MiNK Therapeutics to Participate at Upcoming Investor Conferences

NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September:

  • HC Wainwright 24th Annual Global Investment Conference

    Fireside chat webcast will be available beginning at 7:00 AM ET on September 12th. Registration available at:
  • Baird 2022 Global Healthcare Conference

    Fireside chat will be held at 1:25 PM ET on September 14th. The conference will take place at the InterContinental New York Barclay.

A webcast replay will be available following the conferences and may be accessed on the Events & Presentations page of the Company’s website at .

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit /.

Contact

Kimberly Ha

KKH Advisors

917-291-5744



EN
31/08/2022

Underlying

INKTMINK THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINK THERAPEUTICS INC

 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 F...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast a...

May 5, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and ...

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET. “Throughout 2024, MiNK advanced its mis...

March 18, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Ful...

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a...

March 4, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data i...

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today presented new translational data from its ongoing Phase 2 study o...

February 24, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirem...

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal notice from Nasdaq confirming that the Company has regained compliance with both the minimum bid price and market value of listed securities requirements for conti...

February 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch